Replicel Is On Fire Lately — Data In Feb.
- Thread starter That Guy
- Start date
- Reaction score
- 984
- Reaction score
- 984
- Reaction score
- 984
A new article of Manabu Ohyama (Shiseido) is available since 25.02.20019
Check this: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388497/
Conclusion
The advances have been made in the identification of stem/progenitor cell subsets within HFs. Various techniques to enhance EMI and regenerate HFs adopting these subsets have been developed. However, most investigations were conducted in mice. We are aware that mice and human HF cells share fundamental biological properties but they are distinct [95]. Major morphological and physiological characteristics, such as size and hair cycle, are also different between mouse and human HFs [4, 14]. Seemingly, theoretical basis for human HF regeneration have already been developed, yet a pile of problems still remain unsolved before human HF bioengineering becomes truly possible. The wise use of hiPSCs may enhance opportunity to overcome major technical hurdles and enable better understanding of HF biology, drug discovery, and, ultimately, replacement therapy for intractable hair disorders, which can further be applied to treat other tackling diseases.
Check this: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388497/
Conclusion
The advances have been made in the identification of stem/progenitor cell subsets within HFs. Various techniques to enhance EMI and regenerate HFs adopting these subsets have been developed. However, most investigations were conducted in mice. We are aware that mice and human HF cells share fundamental biological properties but they are distinct [95]. Major morphological and physiological characteristics, such as size and hair cycle, are also different between mouse and human HFs [4, 14]. Seemingly, theoretical basis for human HF regeneration have already been developed, yet a pile of problems still remain unsolved before human HF bioengineering becomes truly possible. The wise use of hiPSCs may enhance opportunity to overcome major technical hurdles and enable better understanding of HF biology, drug discovery, and, ultimately, replacement therapy for intractable hair disorders, which can further be applied to treat other tackling diseases.
- Reaction score
- 984
this is a question for more scientific backgrounded and more experienced members like you. Just want to post it cause it is of Dr. Ohyama (Shiseido) and it deals about Dermal Sheath Cup Cells.
- Reaction score
- 984
https://www.finanzen.net/nachricht/aktien/replicel-reignites-its-first-in-japan-strategy-7270345
Unlike anywhere else in the world, one well-designed cell therapy trial in Japan, approved by their regulatory authorities, has the potential to lead to product market launch. The strategy to bring its products to market first in Japan spans the Company’s entire portfolio. While the Company’s RCH-01 for hair loss due to androgenic alopecia may be launched in Japan much earlier if Shiseido decides to do so, current planning anticipates the potential for all four products to be on the market in Japan by 2022.
Again in 2016, RepliCel’s licensee, Shiseido Company, was one of the first companies to fund, and manufacture a product for use in, a clinical study under the newly enacted Act for the Safety of Regenerative Medicine (ASRM).
RCH-01 – A Japanese clinical study of RepliCel’s RCH-01 treatment for hair loss due to androgenic alopecia, approved by Japan’s Ministry of Health, Labour and Welfare, has been the subject of a clinical study recently completed at Tokyo Medical University Hospital and Toho University Medical Center Ohashi Hospital. The market is now keenly watching Shiseido Company, RepliCel’s licensee of the product for Asia, for any signal regarding its launch of that product in Japan.
READY FOR LAUNCHING RCH-01 RIGHT NOW!!!!!!!!!
Unlike anywhere else in the world, one well-designed cell therapy trial in Japan, approved by their regulatory authorities, has the potential to lead to product market launch. The strategy to bring its products to market first in Japan spans the Company’s entire portfolio. While the Company’s RCH-01 for hair loss due to androgenic alopecia may be launched in Japan much earlier if Shiseido decides to do so, current planning anticipates the potential for all four products to be on the market in Japan by 2022.
Again in 2016, RepliCel’s licensee, Shiseido Company, was one of the first companies to fund, and manufacture a product for use in, a clinical study under the newly enacted Act for the Safety of Regenerative Medicine (ASRM).
RCH-01 – A Japanese clinical study of RepliCel’s RCH-01 treatment for hair loss due to androgenic alopecia, approved by Japan’s Ministry of Health, Labour and Welfare, has been the subject of a clinical study recently completed at Tokyo Medical University Hospital and Toho University Medical Center Ohashi Hospital. The market is now keenly watching Shiseido Company, RepliCel’s licensee of the product for Asia, for any signal regarding its launch of that product in Japan.
READY FOR LAUNCHING RCH-01 RIGHT NOW!!!!!!!!!
- Reaction score
- 686
Don t worry. It has nothing to do with rch-01. The paper is about hipscells. (which are more likely to do tumorgenesis) Which are not part of the rch-01 treatment. hipscells can be used for hair cloning. The article is basicly saying that hair cloning with hipscells is taking some more years to finish. (tsuji has another approach than using hipscells.)
Alexei terkishk (or whatever his name was tries to do cloning with these kind of cells)
hipscells are normal cells returned in a stemcell mode.
Does it means that the trial has been sucessfull?
- Reaction score
- 26
Replicel is Intercytex 2.0.
It pissed me off when this Replicel, has NOTHING in their hand, keeps UPDATING, ANTICIPATING, blah blah blah.
Co-development = Replicel + Shiseido to conduct trial SIMULTANEOUSLY. They broke their PROMISE, yet, they still proudly mention "RCH co-development with Shiseido" in every stupid single letter of theirs. What a shame. If you are following their suck *** newsletter, you will see this fishy pattern. In stead, I wish Replicel went bankrupt, not Cassiopea cause at least, Cassiopea is doing something rather than this f*** off Replicel.
They used to SPECULATE Sep/Oct 18 for trial data release. Men, these people must learn to shut up when they had nothing.
Last edited:
- Reaction score
- 424
I offered to go to the Congress bro and petersonKj and byebyehair were both against it.
- Reaction score
- 984
Bro You should do what You Want and not what others told You to do. Please go for it and do a Record Audio
that Would be very nice bro!- Reaction score
- 26
Ergo money equates with a result? Bill Gates has money too.
- Reaction score
- 424
Ever considered bro that maybe unlike you I don't live on HairLossTalk.com (likely multiple accounts or previously banned) and needlessly pointlessly post unwarranted horse sh*t? Wild accusations? You are lazy and want to be spoon fed everything failing that you just make up lies. You've brought nothing to do the forum but negativity and antagonism.
- Reaction score
- 424
Who died and made you god? Where do you get this entitlement from bro? Manufacturers? Yeah right because one 'manufacturer' can produce everything on the planet right? Common sense, which I know you are lacking in bro, would tell you otherwise. Anyone here with a proper chemistry background would also tell you the same bro. You just keep on lying, rambling and barking.
- Reaction score
- 424
Can a mod please step in and ban petersonKj? Brings nothing to this place.
- Reaction score
- 424
You bring nothing to this forum but ramblings. I accused one and it's pretty f*****g obvious he is a shill. The other you've dreamed up and don't have any major issues that I recall with him. Kane is known here and elsewhere to have issues.